Details of the Drug Combination

General Information of Drug Combination (ID: DCL2XUG)

• Drug Combination Name: Acetohydroxamic Acid + BHV-0223
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Acetohydroxamic Acid (DMYX7NI): Small molecular drug
  BHV-0223 (DMBLM5H): N.A.
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 0.6
  Bliss Independence Score: 0.6
  Loewe Additivity Score: 14.17
  LHighest Single Agent (HSA) Score: 14.17

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Acetohydroxamic Acid

Disease Entry	ICD 11	Status	REF
Urinary tract infection	GC08	Approved	[2]

Acetohydroxamic Acid Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Bacterial Urease (Bact ureC)	TTAS2UO	URE1_KLEAE	Inhibitor	[4]

Acetohydroxamic Acid Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Acetylcholinesterase (ACHE)	OT2H8HG6	ACES_HUMAN	Decreases Activity	[5]

Indication(s) of BHV-0223

Disease Entry	ICD 11	Status	REF
Amyotrophic lateral sclerosis	8B60.0	Phase 1	[3]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018749.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Enzymatic, immunological and phylogenetic characterization of Brucella suis urease. BMC Microbiol. 2008 Jul 19;8:121.
• [5] New bispyridinium oximes: in vitro and in vivo evaluation of their biological efficiency in soman and tabun poisoning. Chem Biol Interact. 2008 Sep 25;175(1-3):413-6.